Vemurafenib: the first drug approved for BRAF-mutant cancer

By G. Bollag, J. Tsai, Jiazhong Zhang, Chao Zhang, P. Ibrahim, K. Nolop, P. Hirth. Nature reviews. Drug discovery, 2012

779 citations recorded by the source corpus.

Subfields: Computational Theory and Mathematics, Molecular Biology, Organic Chemistry

View Paper: https://www.semanticscholar.org/paper/7799b7212e6460d2cff64504efdb6437e1c638d9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Computational Theory and Mathematics

1. W. Jahnke
2. Stephen W. Fesik
3. Roderick E. Hubbard
4. D. Erlanson
5. H. Jhoti

In Molecular Biology

1. Stephen W. Fesik
2. Roderick E. Hubbard
3. Benjamin P. Roscoe

In Organic Chemistry

1. Roderick E. Hubbard
2. Benjamin P. Roscoe

Citations in the corpus

• Resistance to vemurafenib resulting from a novel mutation in the BRAFV600E kinase domain (2013, background): “27; 124–133 ORGINAL ARTICLE tumor regression, resulting in improved progression-free and overall survival in patients with metastatic disease (Bollag et al., 2010, 2012).”
• Twenty years on: the impact of fragments on drug discovery (2016, background): “…of compounds bound to PIM1, and then of compounds bound to the kinase domain of fibroblast growth factor receptor 1 (FGFR1) as a surrogate, until more-potent compounds were successfully crystallized in BRAF, ultimately leading to the clinical candidate, which is approved to treat melanoma 84 .”